Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.
Novel siderophore-linked monobactams with in vitro and in vivo anti-microbial activity against MDR Gram-negative pathogens are described.
Medicinal Chemistry, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, USA.
Mark J
MJ
Mitton-Fry
Joel T
JT
Arcari
Matthew F
MF
Brown
Jeffrey M
JM
Casavant
Steven M
SM
Finegan
Mark E
ME
Flanagan
Hongying
H
Gao
David M
DM
George
Brian S
BS
Gerstenberger
Seungil
S
Han
Joel R
JR
Hardink
Thomas M
TM
Harris
Thuy
T
Hoang
Michael D
MD
Huband
Rebecca
R
Irvine
Manjinder S
MS
Lall
M
M
Megan Lemmon
Chao
C
Li
Jian
J
Lin
Sandra P
SP
McCurdy
John P
JP
Mueller
Lisa
L
Mullins
Mark
M
Niosi
Mark C
MC
Noe
David
D
Pattavina
Joseph
J
Penzien
Mark S
MS
Plummer
Hud
H
Risley
Brandon P
BP
Schuff
Veerabahu
V
Shanmugasundaram
Jeremy T
JT
Starr
Jianmin
J
Sun
Jennifer
J
Winton
Jennifer A
JA
Young
D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D001798:Blood Proteins / Q000737:chemistry; D018360:Crystallography, X-Ray; D004305:Dose-Response Relationship, Drug; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D051379:Mice; D008826:Microbial Sensitivity Tests; D008958:Models, Molecular; D015394:Molecular Structure; D008997:Monobactams / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D013329:Structure-Activity Relationship
D001798:Blood Proteins; D008997:Monobactams